These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 33037409)

  • 21. The Crosstalk of Long Non-Coding RNA and MicroRNA in Castration-Resistant and Neuroendocrine Prostate Cancer: Their Interaction and Clinical Importance.
    Hu CY; Wu KY; Lin TY; Chen CC
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.
    Gong Y; Chippada-Venkata UD; Galsky MD; Huang J; Oh WK
    Prostate; 2015 May; 75(6):616-27. PubMed ID: 25560638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
    Yasumizu Y; Rajabi H; Jin C; Hata T; Pitroda S; Long MD; Hagiwara M; Li W; Hu Q; Liu S; Yamashita N; Fushimi A; Kui L; Samur M; Yamamoto M; Zhang Y; Zhang N; Hong D; Maeda T; Kosaka T; Wong KK; Oya M; Kufe D
    Nat Commun; 2020 Jan; 11(1):338. PubMed ID: 31953400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of novel miR-145-3p regulatory networks on survival in patients with castration-resistant prostate cancer.
    Goto Y; Kurozumi A; Arai T; Nohata N; Kojima S; Okato A; Kato M; Yamazaki K; Ishida Y; Naya Y; Ichikawa T; Seki N
    Br J Cancer; 2017 Jul; 117(3):409-420. PubMed ID: 28641312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
    Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
    Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroRNA-1205 Regulation of FRYL in Prostate Cancer.
    Naidoo M; Levine F; Gillot T; Orunmuyi AT; Olapade-Olaopa EO; Ali T; Krampis K; Pan C; Dorsaint P; Sboner A; Ogunwobi OO
    Front Cell Dev Biol; 2021; 9():647485. PubMed ID: 34386489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting SOX4/PCK2 signaling suppresses neuroendocrine trans-differentiation of castration-resistant prostate cancer.
    Jing N; Tao Z; Du X; Wen Z; Gao WQ; Dong B; Fang YX
    Biol Direct; 2024 Jul; 19(1):56. PubMed ID: 39014441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pirin: a potential novel therapeutic target for castration-resistant prostate cancer regulated by miR-455-5p.
    Arai T; Kojima S; Yamada Y; Sugawara S; Kato M; Yamazaki K; Naya Y; Ichikawa T; Seki N
    Mol Oncol; 2019 Feb; 13(2):322-337. PubMed ID: 30444038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
    Dardenne E; Beltran H; Benelli M; Gayvert K; Berger A; Puca L; Cyrta J; Sboner A; Noorzad Z; MacDonald T; Cheung C; Yuen KS; Gao D; Chen Y; Eilers M; Mosquera JM; Robinson BD; Elemento O; Rubin MA; Demichelis F; Rickman DS
    Cancer Cell; 2016 Oct; 30(4):563-577. PubMed ID: 27728805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HOTAIR is a REST-regulated lncRNA that promotes neuroendocrine differentiation in castration resistant prostate cancer.
    Chang YT; Lin TP; Tang JT; Campbell M; Luo YL; Lu SY; Yang CP; Cheng TY; Chang CH; Liu TT; Lin CH; Kung HJ; Pan CC; Chang PC
    Cancer Lett; 2018 Oct; 433():43-52. PubMed ID: 29944905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.
    Li Y; Donmez N; Sahinalp C; Xie N; Wang Y; Xue H; Mo F; Beltran H; Gleave M; Wang Y; Collins C; Dong X
    Eur Urol; 2017 Jan; 71(1):68-78. PubMed ID: 27180064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer.
    Li JJ; Vasciaveo A; Karagiannis D; Sun Z; Chen X; Socciarelli F; Frankenstein Z; Zou M; Pannellini T; Chen Y; Gardner K; Robinson BD; de Bono J; Abate-Shen C; Rubin MA; Loda M; Sawyers CL; Califano A; Lu C; Shen MM
    bioRxiv; 2023 Jul; ():. PubMed ID: 37502956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroendocrine differentiation in castration resistant prostate cancer. Nuclear medicine radiopharmaceuticals and imaging techniques: A narrative review.
    Usmani S; Orevi M; Stefanelli A; Zaniboni A; Gofrit ON; Bnà C; Illuminati S; Lojacono G; Noventa S; Savelli G
    Crit Rev Oncol Hematol; 2019 Jun; 138():29-37. PubMed ID: 31092382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.
    Beltran H; Oromendia C; Danila DC; Montgomery B; Hoimes C; Szmulewitz RZ; Vaishampayan U; Armstrong AJ; Stein M; Pinski J; Mosquera JM; Sailer V; Bareja R; Romanel A; Gumpeni N; Sboner A; Dardenne E; Puca L; Prandi D; Rubin MA; Scher HI; Rickman DS; Demichelis F; Nanus DM; Ballman KV; Tagawa ST
    Clin Cancer Res; 2019 Jan; 25(1):43-51. PubMed ID: 30232224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting PKLR/MYCN/ROMO1 signaling suppresses neuroendocrine differentiation of castration-resistant prostate cancer.
    Chen WY; Thuy Dung PV; Yeh HL; Chen WH; Jiang KC; Li HR; Chen ZQ; Hsiao M; Huang J; Wen YC; Liu YN
    Redox Biol; 2023 Jun; 62():102686. PubMed ID: 36963289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker.
    Goto Y; Kojima S; Nishikawa R; Kurozumi A; Kato M; Enokida H; Matsushita R; Yamazaki K; Ishida Y; Nakagawa M; Naya Y; Ichikawa T; Seki N
    Br J Cancer; 2015 Sep; 113(7):1055-65. PubMed ID: 26325107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer.
    Zhu S; Tian H; Niu X; Wang J; Li X; Jiang N; Wen S; Chen X; Ren S; Xu C; Chang C; Flores-Morales A; Shang Z; Sun Y; Niu Y
    Oncogene; 2019 Jun; 38(24):4875-4884. PubMed ID: 30770901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer.
    Flores-Morales A; Bergmann TB; Lavallee C; Batth TS; Lin D; Lerdrup M; Friis S; Bartels A; Kristensen G; Krzyzanowska A; Xue H; Fazli L; Hansen KH; Røder MA; Brasso K; Moreira JM; Bjartell A; Wang Y; Olsen JV; Collins CC; Iglesias-Gato D
    Clin Cancer Res; 2019 Jan; 25(2):595-608. PubMed ID: 30274982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.
    Schalken J; Fitzpatrick JM
    BJU Int; 2016 Feb; 117(2):215-25. PubMed ID: 25818596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.